May 14 |
Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ PTH for Adults with Hypoparathyroidism
|
May 13 |
Significant and Sustained Improvements in Renal Function Reported for Adults with Chronic Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide): 2-year Results from Phase 3 PaTHway Trial
|
May 9 |
Latest Clinical and Quality-of-Life Data for TransCon™ PTH (Palopegteriparatide)-Treated Adults with Chronic Hypoparathyroidism to Be Presented at ECE 2024
|
May 8 |
An Update On Ascendis Pharma's Path To Profitability
|
May 6 |
Ascendis Pharma A/S (NASDAQ:ASND) Q1 2024 Earnings Call Transcript
|
May 4 |
Ascendis Pharma A/S (ASND) Q1 2024 Earnings Call Transcript
|
May 4 |
Ascendis Pharma First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
May 2 |
Ascendis Pharma reports Q1 results
|
May 2 |
Ascendis Pharma Reports First Quarter 2024 Financial Results
|
May 1 |
Ascendis Pharma Q1 2024 Earnings Preview
|